Brief: Ascentage Pharma Delivers Oral Presentations On Chinese Studies of Olverembatinib
11/12/2022 19:11
Dec 11 (Reuters) - Ascentage Pharma Group International
6855.HK :
* LIVE FROM ASH 2022 | ASCENTAGE PHARMA DELIVERS ORAL
PRESENTATIONS ON CHINESE STUDIES OF OLVEREMBATINIB (HQP1351) AT
THE ASH ANNUAL MEETING FOR THE FIFTH YEAR, WITH DATA FURTHER
VALIDATING THE DRUG'S LONG-TERM EFFICACY AND SAFETY
* ASCENTAGE PHARMA GROUP INTERNATIONAL - IN CHINESE PIVOTAL
PHASE
II TRIALS, OLVEREMBATINIB SHOWED POSITIVE LONG-TERM SAFETY AND
EFFICACY IN PATIENTS
Source text for Eikon: ID:nPn3CcSRja
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up